FTC: Pharma compound is too strong to swallow.

PositionTriangle

After nearly a yearlong engagement, Talecris Biotherapeutics Inc. and Australia-based CSL Ltd. broke up before reaching the altar. But not because they had a falling out. Blame a third party. CSL's $3.1 billion offer to buy Research Triangle Park-based Talecris, which makes medicine from blood plasma, ran afoul of the Federal Trade Commission, which worried that the deal would give CSL a near monopoly on blood-plasma drugs in the...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT